NTRK2 and metabolic dysfunction-associated steatohepatitis: However, although these studies provide important clues to the role of TrkB in liver fibrosis, there is still a lack of data from clinical studies targeting TrkB, and its differential expression and therapeutic potential in human NASH patients still need to be further validated.